论文部分内容阅读
目的:探讨盐酸舍曲林片对脑卒中患者预防抑郁的临床疗效及其神经功能的改善作用。方法:选取2013年7月—2015年7月期间收治的脑卒中患者70例,按随机数表法将其分为观察组和对照组,每组35例;观察组患者在脑卒中常规治疗的基础上加用盐酸舍曲林片,对照组患者在脑卒中常规治疗的基础上加用同剂量的安慰剂,治疗时间为8周;分别按治疗前、治疗4周和8周时,采用美国国立卫生院神经功能缺损评分量表(NIHSS)、改良Barthel指数量表(MBI)及汉密尔顿抑郁量表(HAMD)评估两组患者神经功能缺损状态、日常生活能力及抑郁发生状况。结果:两组患者治疗前NIHSS评分值、MBI评分值经比较其差异无统计学意义(P>0.05);治疗4周和8周时观察组患者NIHSS评分值分别为(12.06±1.79)分和(6.21±1.37)分,均显著低于对照组为(13.47±2.24)分和(8.55±1.80)分(P<0.05);以及治疗4周和8周时MBI评分值分别为(79.47±4.26)分和(88.97±5.71)分,均显著高于对照组为(71.51±5.50)分和(80.40±6.42)分(P<0.05);治疗4周和8周时观察组患者抑郁的发生率分别为20.00%和8.57%均显著低于对照组为40.86%和48.57%(P<0.05)。结论:盐酸舍曲林片对脑卒中患者抑郁的预防疗效较为显著,可显著降低脑卒中患者抑郁症的发生率,并对患者神经功能和日常生活能力有显著的改善作用。
Objective: To investigate the clinical efficacy of sertraline hydrochloride tablet in preventing stroke in stroke patients and its neurological function. Methods: Seventy patients with stroke were selected from July 2013 to July 2015, and divided into observation group and control group according to random number table method, with 35 cases in each group. The patients in observation group were treated routinely in stroke Based on the addition of sertraline hydrochloride tablets, the control group of patients in the conventional stroke treatment based on the use of the same dose of placebo, the treatment time was 8 weeks; respectively, before treatment, treatment of 4 weeks and 8 weeks, using the United States NIHSS, MBI and HAMD were used to evaluate the neurological deficit status, daily living ability and the incidence of depression in both groups. Results: The scores of NIHSS and MBI in two groups before treatment had no significant difference (P> 0.05). NIHSS scores in observation group were (12.06 ± 1.79) points at 4 and 8 weeks respectively (6.21 ± 1.37) points were significantly lower than those in control group (13.47 ± 2.24) and (8.55 ± 1.80) points respectively (P <0.05). The MBI scores at the 4th and 8th week were (79.47 ± 4.26 ) And (88.97 ± 5.71) points were significantly higher than those in the control group (71.51 ± 5.50) and (80.40 ± 6.42) points (P <0.05). The incidence of depression in the observation group at 4 weeks and 8 weeks 20.00% and 8.57%, respectively, were significantly lower than the control group was 40.86% and 48.57% (P <0.05). Conclusion: Sertraline hydrochloride tablets have significant effect in preventing and treating depression in patients with stroke, and can significantly reduce the incidence of depression in stroke patients and significantly improve the neurological function and daily living ability of patients.